CompanyGraph
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
002566 · SZSE · China
yisheng-pharm.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionPrice-to-book is 1.01×, lower than 95% of its Biotechnology peers (median 2.97×)
- FinancialsAltman Z-Score 3.68: safe zone
- Interpretations3 currently firing — 1 · 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.18%Above 5Y avg (1.00%)
Annual Rate
CNY 0.08Paid unknown
Payout Ratio
99.4%High
Payback Period
84.9 yr
Last Ex-Dividend
May 29, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
High Dividend Payout With FCF And Equity Ratio
→dividend payout intensity
fcf positive 3y
ratio balance equity
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
High Dividend Payout With FCF And Equity Ratio
It pays out most of its earnings, on three years of positive free cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.27BCNY337.18M · vs all stocks (USD)
Trailing P/E
68.70xvs Biotechnology peers
Revenue (TTM)
659.66MCNY97.83M · vs all stocks (USD)
Profit Margin
5.04%vs Biotechnology peers
Beta
0.1370xvs all stocks
52-Week Change
-20.70%vs all stocks
Forward Annual Dividend Yield
1.18%vs all stocks
Market Capitalization
2.27BCNY337.18M · vs all stocks (USD)
Enterprise Value
2.22BCNY329.07M · vs all stocks (USD)
Trailing P/E
68.70xvs Biotechnology peers
Forward P/E
7.63xvs Biotechnology peers
Price to Sales (TTM)
3.45xvs Biotechnology peers
Price to Book (MRQ)
1.01xvs Biotechnology peers
Enterprise to Revenue
3.36xvs Biotechnology peers
Enterprise to EBITDA
43.19xvs Biotechnology peers
Gross Margin
74.96%vs Biotechnology peers
Profit Margin
5.04%vs Biotechnology peers
Operating Margin
4.58%vs Biotechnology peers
Return on Assets (TTM)
0.29%vs Biotechnology peers
Return on Equity (TTM)
1.41%vs Biotechnology peers
Revenue (TTM)
659.66MCNY97.83M · vs all stocks (USD)
Revenue per Share (TTM)
1.99CNYUpdated Aug 19, 2026Quarterly Revenue Growth
12.20%vs Biotechnology peers
Gross Profit (TTM)
484.43MCNY71.84M · vs all stocks (USD)
EBITDA (TTM)
63.13MCNY9.36M · vs all stocks (USD)
Net Income (TTM)
33.28MCNY4.94M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
36.10%vs Biotechnology peers
Operating Cash Flow (TTM)
108.30MCNY16.06M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
69.12MCNY10.25M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0800CNYUpdated Aug 19, 2026Forward Annual Dividend Yield
1.18%vs all stocks
Trailing Annual Dividend Rate
0.0800CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
1.18%vs all stocks
5-Year Average Dividend Yield
1.00%vs all stocks
Payout Ratio
99.40%vs Biotechnology peers
Minority Interest (Equity)
97.76MCNYFY2025 · Dec 31, 2025Revenue
640.17MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
166.50MCNYFY2025 · Dec 31, 2025Gross Profit
473.67MCNYFY2025 · Dec 31, 2025Operating Income
38.84MCNY5.76M · vs all stocks (USD)
Pre-tax Income
30.06MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.13MCNYFY2025 · Dec 31, 2025Net Income
28.93MCNYFY2025 · Dec 31, 2025EBIT
42.68MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
93.98MCNYFY2025 · Dec 31, 2025Research & Development
15.14MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
304.41MCNYFY2025 · Dec 31, 2025Other Operating Expenses
17.66MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
462.33KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.62MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0876CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0876CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
331.04MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
331.04MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
28.93MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
69.11KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
52.49MCNYFY2025 · Dec 31, 2025Free Cash Flow
39.12MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
63.55MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
28.93MCNYFY2025 · Dec 31, 2025Other Non-cash Items
13.31MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-29.65MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
39.90MCNYFY2025 · Dec 31, 2025Capital Expenditures
-13.37MCNYFY2025 · Dec 31, 2025Purchase of Investments
-501.76MCNYFY2025 · Dec 31, 2025Sale of Investments
463.02MCNYFY2025 · Dec 31, 2025Other Investing Activity
-1.30MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-53.42MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
333.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-355.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-45.61MCNYFY2025 · Dec 31, 2025Other Financing Charges
14.36MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-53.25MCNYFY2025 · Dec 31, 2025Shares Outstanding
330.95MSharesUpdated Aug 19, 2026Float Shares
188.43MSharesUpdated Aug 19, 2026% Held by Insiders
50.25%vs all stocks
% Held by Institutions
1.00%vs all stocks
Total Cash (MRQ)
634.94MCNY94.16M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.92CNYUpdated Aug 19, 2026Total Debt (MRQ)
482.42MCNY71.54M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2057xvs Biotechnology peers
Current Ratio (MRQ)
5.86xvs Biotechnology peers
Book Value per Share (MRQ)
6.79CNYUpdated Aug 19, 2026Total Assets
2.96BCNY438.91M · vs all stocks (USD)
Total Current Assets
2.40BCNYFY2025 · Dec 31, 2025Total Liabilities
630.35MCNYFY2025 · Dec 31, 2025Total Non-current Assets
561.82MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
246.25MCNYFY2025 · Dec 31, 2025Total Current Liabilities
384.10MCNYFY2025 · Dec 31, 2025Cash
62.79MCNYFY2025 · Dec 31, 2025Cash Equivalents
759.31KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
63.55MCNYFY2025 · Dec 31, 2025Other Short-term Investments
507.57MCNYFY2025 · Dec 31, 2025Accounts Receivable
158.33MCNYFY2025 · Dec 31, 2025Inventory
1.58BCNYFY2025 · Dec 31, 2025Accounts Payable
11.69MCNYFY2025 · Dec 31, 2025Short-term Debt
290.93MCNYFY2025 · Dec 31, 2025Other Current Liabilities
21.90MCNYFY2025 · Dec 31, 2025Long-term Debt
135.04MCNYFY2025 · Dec 31, 2025Common Stock (Book)
330.95MCNYFY2025 · Dec 31, 2025Retained Earnings
918.25MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.33BCNY345.43M · vs all stocks (USD)
52-Week Low
5.76CNYUpdated Aug 19, 202652-Week High
9.68CNYUpdated Aug 19, 202652-Week Change
-20.70%vs all stocks
Beta
0.1370xvs all stocks
50-Day MA
6.45CNYUpdated Aug 19, 2026200-Day MA
7.65CNYUpdated Aug 19, 2026Avg 10-Day Volume
10.21MSharesUpdated Aug 19, 2026Avg 30-Day Volume
11.65MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.1000CNYUpdated Aug 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 1.01×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 1.01Industry median: 2.97Industry P5: 1.03Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.75Profit Margin: 0.05
Financial Health
Altman Z-Score 3.68: safe zoneNotable
Altman Z-Score: 3.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Organogenesis Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Green Cross Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Enwei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Perspective Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Inhibikase Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Beijing SDL Technology Co. Ltd.
3 interpretationsHigh Dividend Payout With FCF And Equity RatioClose Below 40W SMA With ProfitabilityPrice Below Mean With Profitability And Equity
Hong Tai Electric Industrial Co., Ltd.
3 interpretationsHigh Dividend Payout With FCF And Equity RatioClose Below 40W SMA With ProfitabilityPrice Below Mean With Profitability And Equity
Zhongyeda Electric Company Ltd.
3 interpretationsHigh Dividend Payout With FCF And Equity RatioClose Below 40W SMA With ProfitabilityPrice Below Mean With Profitability And Equity